Phase 1 Type 1 Diabetes Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have never used a GLP-1 receptor agonist medication (a type of diabetes/weight loss drug), or whose last dose of one was at least 6 months before the screening visit.
• For Parts A and B (single-dose and food/medication effect testing): People who are generally healthy, with a BMI between 19 and 30, no significant medical history, and who are considered in good health by the study doctor at a check-up within 28 days before the first dose.
• For Part C (multiple-dose testing in people with obesity who do not have diabetes): People with a BMI between 30 and 45, a total body weight over 50 kg, no diabetes (based on a blood sugar marker called HbA1c being below 6.5%), and whose weight has been stable (less than 5% change) for at least 90 days before screening.
• For Part D (multiple-dose testing in people with type 2 diabetes who are not obese): People with type 2 diabetes, an HbA1c blood sugar level between 7.0% and 10.5%, a BMI between 19 and 30, and who manage their diabetes through diet and/or exercise alone, or with metformin as their only medication.

Who may not be able to join:

• People with a serious or active physical or mental health condition (including depression) that the study doctor believes could interfere with the study, including a history of pancreatitis, gallbladder disease, kidney, heart, blood, liver, lung (including chronic asthma), hormonal, nerve, digestive, vascular, immune, thyroid, adrenal, or metabolic conditions, active infection, or cancer that is clinically significant or needs treatment.
• People who currently have symptoms of diabetic eye disease (diabetic retinopathy), or who had an eye examination showing this condition within the past year.
• People found to have a significant imbalance in certain minerals in their blood (such as low potassium, calcium, or magnesium) at the screening visit.
• People with a condition that the study doctor believes could cause mineral imbalances in the blood, such as an eating disorder.
• People with a history of fainting, heart palpitations, or unexplained dizziness.
• People with a current or past significant heart condition or abnormal heart rhythm.
• People who have had a pacemaker or defibrillator implanted.
• People who have used GLP-1 receptor agonist medications, systemic steroids, immunosuppressant therapies, or chemotherapy agents in the 6 months before screening, or who are expected to use these during the study.
• People who previously stopped using a GLP-1 receptor agonist medication because of severe side effects such as nausea, constipation, diarrhoea, or vomiting.

Important: Always verify eligibility with the trial site directly before applying.